Literature DB >> 26989656

The Effectiveness of Multiple Electrode Radiofrequency Ablation in Patients with Hepatocellular Carcinoma with Lesions More than 3 cm in Size and Barcelona Clinic Liver Cancer Stage A to B2.

Chen-Chun Lin1, Ya-Ting Cheng1, Wei-Ting Chen M1, Shi-Ming Lin1.   

Abstract

Outcomes of hepatocellular carcinoma (HCC) lesions >3.0 cm in size including Barcelona Clinic Liver Cancer (BCLC) stage B after radiofrequency ablation (RFA) with a single electrode remain unsatisfactory. This study aimed to investigate the outcomes of RFA with multiple electrodes (ME-RFA) for HCC tumors 3.1-7.0 cm in size and BCLC stage B. This retrospective study included 70 consecutive patients with 58 medium- (3.1-5.0 cm) and 17 large- (5.1-7.0 cm) sized HCCs after ME-RFA using a controller. Outcomes in terms of complete response, primary technique effectiveness, local tumor progression, and overall survival were investigated. After 1-4 applications of ME-RFA, the rates of complete response and PTE in medium-sized tumors were 79.3% and 91.4%, respectively, and in large tumors were 76.5% and 94.1%, respectively. Overall, the major complication rate was 5.7%. After a median 21-month follow-up period, both two- and three-year estimated overall survival rates were above 80%. There were no significant differences in overall survival and local tumor progression rates between medium- and large-size tumors and among BCLC stages A, B1 and B2. A complete response to ME-RFA was the only significant factor associated with improved survival (p=0.008). In conclusion, ME-RFA can effectively treat 3.1-7.0-cm sized HCCs with a comparable outcome between medium- and large-size tumors and among BCLA stages A to B2.

Entities:  

Keywords:  Barcelona Clinic Liver Cancer; Hepatocellular carcinoma; Multiple-electrode; Radiofrequency ablation; Survival

Year:  2015        PMID: 26989656      PMCID: PMC4789949          DOI: 10.1159/000367755

Source DB:  PubMed          Journal:  Liver Cancer        ISSN: 1664-5553            Impact factor:   11.740


  33 in total

1.  Multiple-electrode radiofrequency ablation creates confluent areas of necrosis: in vivo porcine liver results.

Authors:  Paul F Laeseke; Lisa A Sampson; Dieter Haemmerich; Christopher L Brace; Jason P Fine; Tina M Frey; Thomas C Winter; Fred T Lee
Journal:  Radiology       Date:  2006-08-23       Impact factor: 11.105

2.  A randomized controlled trial of radiofrequency ablation with ethanol injection for small hepatocellular carcinoma.

Authors:  Shuichiro Shiina; Takuma Teratani; Shuntaro Obi; Shinpei Sato; Ryosuke Tateishi; Tomonori Fujishima; Takashi Ishikawa; Yukihiro Koike; Haruhiko Yoshida; Takao Kawabe; Masao Omata
Journal:  Gastroenterology       Date:  2005-07       Impact factor: 22.682

3.  Management of hepatocellular carcinoma in Japan: Consensus-Based Clinical Practice Guidelines proposed by the Japan Society of Hepatology (JSH) 2010 updated version.

Authors:  Masatoshi Kudo; Namiki Izumi; Norihiro Kokudo; Osamu Matsui; Michiie Sakamoto; Osamu Nakashima; Masamichi Kojiro; Masatoshi Makuuchi
Journal:  Dig Dis       Date:  2011-08-09       Impact factor: 2.404

Review 4.  Local ablation for hepatocellular carcinoma in taiwan.

Authors:  Shi-Ming Lin
Journal:  Liver Cancer       Date:  2013-04       Impact factor: 11.740

5.  Hepatocellular carcinoma: radio-frequency ablation of medium and large lesions.

Authors:  T Livraghi; S N Goldberg; S Lazzaroni; F Meloni; T Ierace; L Solbiati; G S Gazelle
Journal:  Radiology       Date:  2000-03       Impact factor: 11.105

6.  Small hepatocellular carcinoma in cirrhosis: randomized comparison of radio-frequency thermal ablation versus percutaneous ethanol injection.

Authors:  Riccardo A Lencioni; Hans-Peter Allgaier; Dania Cioni; Manfred Olschewski; Peter Deibert; Laura Crocetti; Holger Frings; Joerg Laubenberger; Ina Zuber; Hubert E Blum; Carlo Bartolozzi
Journal:  Radiology       Date:  2003-05-20       Impact factor: 11.105

Review 7.  Heterogeneity of patients with intermediate (BCLC B) Hepatocellular Carcinoma: proposal for a subclassification to facilitate treatment decisions.

Authors:  Luigi Bolondi; Andrew Burroughs; Jean-François Dufour; Peter R Galle; Vincenzo Mazzaferro; Fabio Piscaglia; Jean Luc Raoul; Bruno Sangro
Journal:  Semin Liver Dis       Date:  2013-02-08       Impact factor: 6.115

8.  Radiofrequency ablation: simultaneous application of multiple electrodes via switching creates larger, more confluent ablations than sequential application in a large animal model.

Authors:  Christopher L Brace; Lisa A Sampson; J Louis Hinshaw; Neil Sandhu; Fred T Lee
Journal:  J Vasc Interv Radiol       Date:  2008-11-18       Impact factor: 3.464

9.  Risk factors of survival after percutaneous radiofrequency ablation of hepatocellular carcinoma.

Authors:  Zhen-Wei Peng; Yao-Jun Zhang; Min-Shan Chen; Hui-Hong Liang; Jin-Qing Li; Ya-Qi Zhang; Wan Y Lau
Journal:  Surg Oncol       Date:  2007-09-14       Impact factor: 3.279

10.  Large liver tumors: protocol for radiofrequency ablation and its clinical application in 110 patients--mathematic model, overlapping mode, and electrode placement process.

Authors:  Min-Hua Chen; Wei Yang; Kun Yan; Ming-Wu Zou; Luigi Solbiati; Ji-Bin Liu; Ying Dai
Journal:  Radiology       Date:  2004-05-27       Impact factor: 11.105

View more
  16 in total

Review 1.  Intrahepatic recurrence of hepatocellular carcinoma after resection: an update.

Authors:  Maria Tampaki; George Vasileios Papatheodoridis; Evangelos Cholongitas
Journal:  Clin J Gastroenterol       Date:  2021-03-27

2.  Advances and Future Directions in the Treatment of Hepatocellular Carcinoma.

Authors:  Ashil J Gosalia; Paul Martin; Patricia D Jones
Journal:  Gastroenterol Hepatol (N Y)       Date:  2017-07

3.  Multibipolar Radiofrequency Ablation for the Treatment of Mass-Forming and Infiltrative Hepatocellular Carcinomas > 5 cm: Long-Term Results.

Authors:  Gisele N'Kontchou; Jean-Charles Nault; Olivier Sutter; Valerie Bourcier; Emmanuelle Coderc; Veronique Grando; Pierre Nahon; Nathalie Ganne-Carrié; Abou Diallo; Nicolas Sellier; Olivier Seror
Journal:  Liver Cancer       Date:  2018-06-28       Impact factor: 11.740

4.  Gold nanorod-based poly(lactic-co-glycolic acid) with manganese dioxide core-shell structured multifunctional nanoplatform for cancer theranostic applications.

Authors:  Lei Wang; Dong Li; Yongwei Hao; Mengya Niu; Yujie Hu; Hongjuan Zhao; Junbiao Chang; Zhenzhong Zhang; Yun Zhang
Journal:  Int J Nanomedicine       Date:  2017-04-13

5.  Radiofrequency Ablation (RFA) Combined with Transcatheter Arterial Chemoembolization (TACE) for Patients with Medium-to-Large Hepatocellular Carcinoma: A Retrospective Analysis of Long-Term Outcome.

Authors:  Weiwen Liu; Huihong Xu; Xihui Ying; Dengke Zhang; Linqiang Lai; Linyou Wang; Jianfei Tu; Jiansong Ji
Journal:  Med Sci Monit       Date:  2020-07-15

6.  Radiofrequency ablation of hepatocellular carcinoma: a meta-analysis of overall survival and recurrence-free survival.

Authors:  Andrea Casadei Gardini; Giorgia Marisi; Matteo Canale; Francesco Giuseppe Foschi; Gabriele Donati; Giorgio Ercolani; Martina Valgiusti; Alessandro Passardi; Giovanni Luca Frassineti; Emanuela Scarpi
Journal:  Onco Targets Ther       Date:  2018-10-05       Impact factor: 4.147

7.  Theranostic nanosensitizers for highly efficient MR/fluorescence imaging-guided sonodynamic therapy of gliomas.

Authors:  Hongmei Liu; Meijun Zhou; Zonghai Sheng; Yu Chen; Chih-Kuang Yeh; Wenting Chen; Jia Liu; Xin Liu; Fei Yan; Hairong Zheng
Journal:  J Cell Mol Med       Date:  2018-08-29       Impact factor: 5.310

8.  Priming of Sorafenib Prior to Radiofrequency Ablation Does Not Increase Treatment Effect in Hepatocellular Carcinoma.

Authors:  Bruno Bockorny; Andrea J Bullock; Thomas A Abrams; Salomao Faintuch; David C Alsop; S Nahum Goldberg; Muneeb Ahmed; Rebecca A Miksad
Journal:  Dig Dis Sci       Date:  2021-07-23       Impact factor: 3.487

9.  Integrating interventional oncology in the treatment of liver tumors.

Authors:  D Putzer; P Schullian; E Braunwarth; M Fodor; F Primavesi; B Cardini; T Resch; R Oberhuber; M Maglione; C Margreiter; S Schneeberger; S Stättner; D Öfner-Velano; W Jaschke; R J Bale
Journal:  Eur Surg       Date:  2018-04-13       Impact factor: 0.953

10.  Efficacy of Percutaneous Thermal Ablation Combined With Transarterial Embolization for Recurrent Hepatocellular Carcinoma After Hepatectomy and a Prognostic Nomogram to Predict Survival.

Authors:  Zhuhui Yuan; Yang Wang; Caixia Hu; Wenfeng Gao; Jiasheng Zheng; Wei Li
Journal:  Technol Cancer Res Treat       Date:  2018-01-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.